Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease

Table 1

Comparison of clinical and biochemical characteristics between diabetic subjects with the Metabolic Syndrome and the reference group.

Characteristic	MetS	Reference group	value
	Age (years)	56 ± 10		48.5 ± 13.7	<0.0001
Women, (%)	138 (64.2)	206 (67.1)	0.55
FPG (mg/dL)	136 (112–181)	90 (85–95)	<0.0001
HbA1c (%)	5.4 (4.4–7.5)	3.9 (3.6–4.2)	<0.0001
BMI (kg/m^2)	30.8 ± 5	26.5 ± 4.2	<0.0001
WC (cm)	100 ± 9.9	87.4 ± 11.9	<0.0001
Men ≥ 90 cm, (%)	77 (35.8)	54 (17.5)	<0.0001
Women ≥ 80 cm, (%)	138 (64.2)	138 (44.9)	<0.0001
HDL-c (mg/dL)	35 (30–41)	46.4 (37.2–55.4)	<0.0001
Men < 40 mg/dL, (%)	63 (29.3)	49 (15.9)	0.001
Women < 50 mg/dL, (%)	126 (58.6)	111 (36.1)	<0.0001
Hypertension, (%)	129 (60)	40 (13)	<0.0001
Triglycerides (mg/dL)	205 (134–270)	118 (88–150)	<0.0001
≥150 mg/dL, (%)	152 (70)	79 (25.7)
PAI-1 (ng/mL)	58.4 ± 21	49.9 ± 16	0.026
Current smoking, (%)	50 (23)	62 (20.2)	0.46
FH of AT, (%)	41 (19)	43 (14)	0.16

Continuous variables with normal distribution are expressed as mean ± standard deviation. Continuous variables with nonnormal distribution are expressed as median (interquartile range). Categorical variables are expressed as total number and percentages. MetS: the Metabolic Syndrome; FPG: fasting plasma glucose; HbA1c: glycosylated hemoglobin; BMI: body mass index; WC: waist circumference; HDL-c: high-density lipoprotein cholesterol; PAI-1: plasminogen activator inhibitor type-1; FH of AT: familial history of atherothrombotic disease.